Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies

Executive Summary

As novel cell and gene therapies edge closer to the US market, reimbursement for expensive, long-lasting treatments remains uncertain. AmerisourceBergen Senior VP-Strategy & Commercialization Amy Grogg predicts the first launches will involve many different reimbursement models.

You may also be interested in...



Spark's Hemophilia B Gene Therapy SPK9001 Packs A Punch And Saves Big Bucks

A New England Journal of Medicine publication and editorial highlighted a small study of ten patients in which one infusion of Spark/Pfizer's SPK9001 gene therapy "nearly completely eliminated" the need for factor IX clotting products, saving $200,000 per patient per year.

Cell And Gene Therapies: Where Few Standard Rules Apply

Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel